The Stem Cell Network (SCN) is pleased to announce the first of two national research funding competitions planned for SCN’s 2025-2029 funding cycle. This new competition will support world-class, translational,… Read More
TORONTO, ON – The National Advisory Committee on Immunization’s (NACI) annual Statement on Seasonal Influenza Vaccines for 2024-2025 continues to recommend Fluzone® High-Dose Quadrivalent among the preferential influenza vaccines, over standard dose… Read More
The marketing authorization for SKYRIZI® (risankizumab) marks its fourth approved indication in the European Union The approval is supported by data from two pivotal Phase 3 trials: The INSPIRE induction trial1 and… Read More
VANCOUVER, BC – Augurex Life Sciences Corp. is pleased to announce that it will be presenting two posters at the upcoming Association for Diagnostic & Laboratory Medicine (ADLM 2024) in… Read More
VANCOUVER, BC – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, announced the… Read More
